Why Express Scripts’ Exclusion List for 2019 Is the Biggest Update Ever

Express Scripts just released its 2019 Formulary Exclusion list, marking a dramatic expansion in categories--including new disease areas thought too sensitive or rare to be managed by something as blunt as an exclusion list. In short, Express Scripts' new exclusion update is one of the most aggressive in years. Jeremy Schafer, SVP, Director, Payer Access Solutions, analyzes what the announcement means to payers.

Will American Patients First Deliver on Its Pledge?

What will the American Patients First initiative mean for payers? Will it deliver on lowering drug prices and improving affordability for patients? Andrew Cournoyer, Vice President, Payer Access Solutions, addresses these questions as he breaks down what we know and don’t know about the Trump administration’s recent announcement.

Oncology Coverage Policies: How to Help Payers Stay Ahead of the Scientific Curve

Janet Serluco, Vice President, Director, Payer Access Solutions, highlights the tremendous activity in oncology drug development. With 16 new oncology drugs approved by the FDA in 2017 alone, what strategies are payers adopting in future budget planning, and how do payers keep up with new oncology agents and expanding indications?

Survey Results: The Gene Therapy Revolution, Are Payers Ready?

Gene therapy has moved from the realm of science fiction to reality and is now likely to play a major role in how we will treat numerous diseases. Jeremy Schafer, SVP, Director, Payer Access Solutions, examines the promise of gene therapy and shares the results of a recent Precision for Value Rapid Pulse™ survey of payers and IDN decision makers on current and future challenges of gene therapy.

Catch Up With Precision’s Thought Leaders on Demand: Recorded Webinars Now Available

Did you catch one of our recent live webinars? If you missed one, you can still view the webinar recording on demand. Get expert guidance from one of Precision’s thought leaders.

2018-07-24T18:28:50+00:00By |